Mechanisms of mdma (ecstasy)-induced oxidative stress, mitochondrial dysfunction, and organ damage

Current Pharmaceutical Biotechnology

Volumn 11, Issue 5, 2010, Pages 434-443

  Song, Byoung Joon ^a   Moon, Kwan Hoon ^a   Upreti, Vijay V ^b,d   Eddington, Natalie D ^a   Lee, Insong J ^c  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c NOTRE DAME OF MARYLAND UNIVERSITY   (United States)

^d Discovery Medicine and Clinical Pharmacology   (United States)

Author keywords

Functional redox proteomics; MDMA; Metabolism; Mitochondrial dysfunction; Organ damage; Oxidative nitrosative stress; Protein oxidation

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; BIOTIN; CYSTEINE; MALEIMIDE; MITOCHONDRIAL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG POTENTIATION; HUMAN; NITROSATIVE STRESS; NONHUMAN; ORGAN INJURY; OXIDATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEOMICS; RAT; TISSUE INJURY;

ANIMALS; HALLUCINOGENS; HUMANS; MITOCHONDRIA; MODELS, BIOLOGICAL; MULTIPLE ORGAN FAILURE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; OXIDATIVE STRESS; RATS; VISCERA;

RATTUS;

EID: 77956563187     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920110791591436     Document Type: Article

References (107)

1. Landry, M. J. MDMA: a review of epidemiologic data. J. Psychoactive Drugs, 2002, 34 (2), 163-169.
2. Schifano,F.; Corkery, J.; Deluca, P.; Oyefeso, A.; Ghodse, A. H. Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994-2003). J. Psychopharmacol., 2006, 20 (3), 456-463.
3. Reid, L. W.; Elifson, K. W.; Sterk, C. E. Ecstasy and gateway drugs: initiating the use of ecstasy and other drugs. Ann. Epidemiol., 2007, 17 (1), 74-80.
4. Henry, J.A.; Hill, I.R. Fatal interaction between ritonavir and MDMA. Lancet, 1998, 352 (9142), 1751-1752.
5. Harrington, R. D.; Woodward, J. A.; Hooton, T. M.; Horn, J. R. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch. Intern. Med., 1999, 159 (18), 2221-2224.
6. Kuypers, K. P.; Samyn, N.; Ramaekers, J. G. MDMA and alcohol effects, combined and alone, on objective and subjective measures of actual driving performance and psychomotor function. Psychopharmacology, 2006, 187 (4), 467-475.
7. Fineschi, V.; Centini, F.; Mazzeo, E.; Turillazzi, E. Adam (MDMA) and Eve (MDEA) misuse: an immunohistochemical study on three fatal cases. Forensic Sci. Int., 1999, 104 (1), 65-74.
8. Lai, T. I.; Hwang, J. J.; Fang, C. C.; Chen, W. J. Methylene 3, 4 dioxymethamphetamine-induced acute myocardial infarction Ann. Emerg. Med., 2003, 42 (6), 759-762.
9. Cerretani, D.; Riezzo, I.; Fiaschi, A. I.; Centini, F.; Giorgi, G.; D'Errico, S.; Fiore, C.; Karch, S. B.; Neri, M.; Pomara, C.; Turillazzi, E.; Fineschi, V. Cardiac oxidative stress determination and myocardial morphology after a single ecstasy (MDMA) administration in a rat model. Int. J. Legal Med., 2008, 122 (6), 461-469.
10. Ellis, A. J.; Wendon, J. A.; Portmann, B.; Williams, R. Acute liver damage and ecstasy ingestion. Gut, 1996, 38 (3), 454-458.
11. Andreu, V.; Mas, A.; Bruguera, M.; Salmeron, J. M.; Moreno, V.; Nogué, S.; Rodés, J. Ecstasy: a common cause of severe acute hepatotoxicity. J. Hepatol., 1998, 29 (3), 394-397.
12. Beitia, G.; Cobreros, A.; Sainz, L.; Cenarruzabeitia, E. Ecstasyinduced toxicity in rat liver. Liver, 2000, 20 (1), 8-15.
13. Carvalho, M.; Hawksworth, G.; Milhazes, N.; Borges, F.; Monks, T. J.; Fernandes, E.; Carvalho, F.; Bastos, M. L. Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renal proximal tubular cells. Arch. Toxicol., 2002, 76 (10), 581-588.
14. Ninkovic, M.; Selakovic, V.; Dukic, M.; Milosavljevic, P.; Vasiljevic, I.; Jovanovic, M.; Malicevic, Z. Oxidative stress in rat kidneys due to 3,4-methylenedioxymethamphetamine (ecstasy) toxicity. Nephrology, 2007, 13 (1): 33-37.
15. Campbell, G. A.; Rosner, M. H. The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney. Clin. J. Am. Soc. Nephrol., 2008, 3 (6), 1852-1860.
16. Mas, M.; Farré, M.; de la Torre, R.; Roset, P. N.; Ortuño, J.; Segura, J.; Camí, J. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxy methamphetamine in humans. J. Pharmacol. Exp. Ther., 1999, 290 (1), 136-145.
17. Barenys, M.; Macia, N.; Camps, L.; de Lapuente, J.; Gomez-Catalan, J.; Gonzalez-Linares, J.; Borras, M.; Rodamilans, M.; Llobet, J. M. Chronic exposure to MDMA (ecstasy) increases DNA damage in sperm and alters testes histopathology in male rats. Toxicol. Lett., 2009, 191 (1), 40-46.
18. Connor, T. J.; McNamara, M. G.; Finn, D.; Currid, A.; O'Malley, M.; Redmond, A. M.; Kelly, J. P.; Leonard, B. E. Acute 3,4-methylenedioxymethamphetamine (MDMA) administration produces a rapid and sustained suppression of immune function in the rat. Immunopharmacology, 1998, 38 (3), 253-260.
19. Quinton, M. S.; Yamamoto, B. K. Causes and consequences of methamphetamine and MDMA toxicity. AAPS J., 2006, 8 (2): E337-E347.
20. Capela, J. P.; Carmo, H.; Remião, F.; Bastos, M. L.; Meisel, A.; Carvalho, F. Molecular and cellular mechanisms of ecstasyinduced neurotoxicity: an overview. Mol. Neurobiol., 2009, 39 (3), 210-271.
21. Bai, F.; Jones, D. C.; Lau, S. S.; Monks, T. J. Serotonergic neurotoxicity of 3,4-(+/-)-methylenedioxyamphetamine and 3,4-(+/-)-methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of gamma-glutamyl transpeptidase. Chem. Res. Toxicol., 2001, 14 (7), 863-870.
22. de la Torre, R.; Farre, M.; Roset, P. N.; Pizarro, N.; Abanades, S.; Segura, M.; Segura, J.; Camí, J. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther. Drug Monit., 2004, 26 (2), 137-144.
23. O'Shea, E.; Escobedo, I.; Orio, L.; Sanchez, V.; Navarro, M.; Green, A. R.; Colado, M. I. Elevation of ambient room temperature has differential effects on MDMA-induced 5-HT and dopamine release in striatum and nucleus accumbens of rats. Neuropsychopharmacology, 2005, 30 (7), 1312-1323.
24. Green, A. R.; O'Shea, E.; Colado, M. I. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur. J. Pharmacol., 2004, 500 (1-3), 3-13.
25. Bindoli, A.; Rigobello, M. P., Deeble, D. J. Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radic. Biol. Med., 1992, 13 (4), 391-405.
26. Milhazes, N.; Cunha-Oliveira, T.; Martins, P.; Garrido, J.; Oliveira, C,; Rego, A. C.; Borges, F. Synthesis and cytotoxic profile of 3,4-methylenedioxymethamphetamine (ecstasy) and its metabolites on undifferentiated PC12 cells: A putative structure-toxicity relationship. Chem. Res. Toxicol., 2006, 19 (10), 1294-1304.
27. Carvalho, M.; Remião, F.; Milhazes, N.; Borges, F.; Fernandes, E.; Carvalho, F.; Bastos, M. L. The toxicity of N-methyl-alphamethyldopamine to freshly isolated rat hepatocytes is prevented by ascorbic acid and N-acetylcysteine. Toxicology, 2004, 200 (2-3), 193-203.
28. Bolton, J. L.; Trush, M. A.; Penning, T. M.; Dryhurst, G.; Monks, T. J. Role of quinones in toxicology. Chem. Res. Toxicol., 2000, 13 (3), 135-160.
29. Montiel-Duarte, C.; Ansorena, E.; Lopez-Zabalza, M. J.; Cenarruzabeitia, E.; Iraburu, M. J.; Cenarruzabeitia, E.; Iraburu, M. J. Role of reactive oxygen species, glutathione and NF-kappaB in apoptosis induced by 3,4-methylenedioxy methamphetamine (Ecstasy) on hepatic stellate cells. Biochem. Pharmacol., 2004, 67 (6), 1025-1033.
30. Miller, R. T.; Lau, S. S.; Monks, T. J. 2,5-Bis-(glutathion-S-yl)-alpha-methyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations. Eur. J. Pharmacol., 1997, 323 (2-3), 173-180.
31. Fisher, A. A.; Labenski, M. T.; Malladi, S.; Gokhale, V.; Bowen, M. E.; Milleron, R. S.; Bratton, S. B.; Monks, T. J.; Lau, S. S. Quinone electrophiles selectively adduct electrophile binding motifs within cytochrome c. Biochemistry, 2007, 46 (39), 11090-11100.
32. Paris, J. M.; Cunningham, K. A. Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA). Brain Res. Bull., 1992, 28 (1), 115-119.
33. Carvalho, M.; Remião, F.; Milhazes, N.; Borges, F.; Fernandes, E.; Monteiro Mdo, C.; Gonçalves, M. J.; Seabra, V.; Amado, F.; Carvalho, F.; Bastos, M. L. Metabolism is required for the expression of ecstasy-induced cardiotoxicity in vitro. Chem. Res. Toxicol., 2004, 17 (5), 623-632.
34. Jayanthi, S.; Ladenheim, B.; Andrews, A. M.; Cadet, J. L. Overexpression of human copper/zinc superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxymethamphetamine (Ecstasy). Neuroscience, 1999, 91 (4), 1379-1387.
35. Alvarenga, T. A.; Andersen, M. L.; Ribeiro, D. A.; Araujo, P.; Hirotsu, C.; Costa, J. L.; Battisti, M. C.; Tufik, S. Single exposure to cocaine or ecstasy induces DNA damage in brain and other organs of mice. Addict. Biol., 2010, 15 (1), 96-99.
36. Alves, E.; Binienda, Z.; Carvalho, F.; Alves, C. J.; Fernandes, E.; de Lourdes Bastos, M.; Tavares, M. A.; Summavielle, T. Acetyl-Lcarnitine provides effective in vivo neuroprotection over 3,4-methylenedioximethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain. Neuroscience, 2009, 158 (2), 514-523.
37. Darvesh, A. S.; Yamamoto, B. K.; Gudelsky, G. A. Evidence for the involvement of nitric oxide in 3,4-methylenedioxymethamphetamine-induced serotonin depletion in the rat brain. J. Pharmacol. Exp. Ther., 2005, 312 (2), 694-701.
38. Zheng, Y.; Laverty, R. Role of brain nitric oxide in (+/-)3,4-methylenedioxy methamphetamine (MDMA)-induced neurotoxicity in rats. Brain Res., 1998, 795 (1-2), 257-263.
39. Yamamoto, B. K.; Bankson, M. G. Amphetamine neurotoxicity: Cause and consequence of oxidative stress. Crit. Rev. Neurol., 2005, 17 (2), 87-117.
40. Yamamoto, B. K.; Raudensky, J. The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. J. Neuroimmune Pharmacol., 2008, 3 (4), 203-217.
41. Amacher, D.E. Drug-associated mitochondrial toxicity and its detection. Curr. Med. Chem., 2005, 12 (16), 1829-1839.
42. Begriche, K.; Igoudjil, A.; Pessayre, D.; Fromenty, B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion, 2006, 6 (1), 1-28.
43. Lin, M. T.; Beal. M. F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 2006, 443 (7113), 787-795.
44. Moon, K. H.; Upreti, V. V.; Yu, L. R.; Lee, I. J.; Ye, X.; Eddington, N. D.; Veenstra, T. D.; Song, B. J. Mechanism of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated mitochondrial dysfunction in rat liver. Proteomics, 2008, 8 (18), 3906-3918.
45. Gow, A. J.; Farkouh, C. R.; Munson, D. A.; Posencheg, M. A.; Ischiropoulos, H. Biological significance of nitric oxide-mediated protein modifications. Am. J. Physiol. Lung Cell Mol. Physiol., 2004, 287 (2), L262-L268.
46. Pacher, P.; Beckman, J. S.; Liaudet, L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev., 2007, 87(1), 315-424.
47. Radi, R.; Beckman, J. S.; Bush, K. M.; Freeman, B. A. Peroxynitrite oxidation of sulfhydryls: The cytotoxic potential of superoxide and nitric oxide. J. Biol. Chem., 1991, 266 (7), 4244-4250.
48. Cardoso, S. M.; Pereira, C.; Oliveira, R. Mitochondrial function is differentially affected upon oxidative stress. Free Radic. Biol. Med., 1999, 26 (1-2), 3-13.
49. Murray, J.; Taylor, S. W.; Zhang, B.; Ghosh, S. S.; Capaldi, R. A. Oxidative damage to mitochondrial complex I due to peroxynitrite. Identification of reactive tyrosines by mass spectrometry. J. Biol. Chem., 2003, 278 (39), 37223-37230.
50. Sprague, J. E.; Nichols, D. E. The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J. Pharmacol. Exp. Ther., 1995, 273 (2), 667-673.
51. Suh, S. K.; Hood, B. L.; Kim, B. J.; Conrads, T. P.; Veenstra, T. D.; Song, B. J. Identification of oxidized mitochondrial proteins in alcohol-exposed human hepatoma cells and mouse liver. Proteomics, 2004, 4 (11), 3401-3412.
52. Kim, B. J.; Hood, B. L.; Aragon, R. A.; Hardwick, J. P.; Conrads, T. P.; Veenstra, T. D.; Song, B. J. Increased oxidation and degradation of cytosolic proteins in alcohol-exposed mouse liver and hepatoma cells. Proteomics, 2006, 6 (4), 1250-1260.
53. Moon, K. H.; Hood, B. L.; Kim, B. J.; Hardwick, J. P.; Conrads, T. P.; Veenstra, T. D.; Song, B. J. Inactivation of oxidized and S-nitrosylated mitochondrial proteins in alcoholic fatty liver of rats. Hepatology, 2006, 44 (5), 1218-1230.
54. Moon, K. H.; Hood, B. L.; Mukhopadhyay, P.; Rajesh, M.; Abdelmegeed, M. A.; Kwon, Y. I.; Conrads, T. P.; Veenstra, T. D.; Song, B. J.; Pacher, P. Oxidative inactivation of key mitochondrial proteins leads to dysfunction and injury in hepatic ischemia reperfusion. Gastroenterology, 2008, 135 (4), 1344-1357.
55. Berlett, B. S.; Stadtman, E. R. Protein oxidation in aging, disease, and oxidative stress. J. Biol. Chem., 1997, 272 (33), 20313-20316.
56. Moon, K. H.; Kim, B. J.; Song, B. J. Inhibition of mitochondrial aldehyde dehydrogenase by nitric oxide-mediated S-nitrosylation. FEBS Lett., 2005, 579 (27), 6115-6120.
57. Moon, K. H.; Abdelmegeed, M. A.; Song, B. J. Inactivation of cytosolic aldehyde dehydrogenase via S-nitrosylation in ethanolexposed rat liver. FEBS Lett., 2007, 581 (21), 3967-3972.
58. Gow, A. J.; Duran, D.; Malcolm, S.; Ischiropoulos, H. Effects of peroxynitrite-induced protein modifications on tyrosine phosphorylation and degradation. FEBS Lett., 1996, 385 (1-2), 63-66.
59. Widmer, R.; Kaiser, B.; Engels, M.; Jung, T.; Grune, T. Hyperammonemia causes protein oxidation and enhanced proteasomal activity in response to mitochondria-mediated oxidative stress in rat primary astrocytes. Arch. Biochem. Biophys., 2007, 464 (1), 1-11.
60. Kim, J. R.; Yoon, H. W.; Kwon, K. S.; Lee, S. R.; Rhee, S. G. Identification of proteins containing cysteine residues that are sensitive to oxidation by hydrogen peroxide at neutral pH. Anal. Biochem., 2000, 283 (2), 214-221.
61. Venkatraman, A.; Landar, A.; Davis, A. J.; Ulasova, E.; Page, G.; Murphy, M. P.; Darley-Usmar, V.; Bailey, S. M. Oxidative modification of hepatic mitochondria protein thiols: effect of chronic alcohol consumption. Am. J. Physiol. Gastrointest. Liver Physiol., 2004, 286 (4), G521-G527.
62. Sethuraman, M.; McComb, M. E.; Heibeck, T.; Costello, C. E.; Cohen, R. A. Isotope-coded affinity tag approach to identify and quantify oxidant-sensitive protein thiols. Mol. Cell Proteomics, 2004, 3 (3), 273-278.
63. Unlü, M.; Morgan, M. E.; Minden, J. S. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis, 1997, 18 (11), 2071-2077.
64. Tonge, R.; Shaw, J.; Middleton, B.; Rowlinson, R.; Rayner, S.; Young, J.; Pognan, F.; Hawkins, E.; Currie, I.; Davison, M. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics, 2001, 1 (3), 377-396.
65. Park, K. S.; Cho, S. Y.; Kim, H.; Paik, Y. K. Proteomic alterations of the variants of human aldehyde dehydrogenase isozymes correlate with hepatocellular carcinoma. Int. J. Cancer, 2002, 97 (2), 261-265.
66. Kim, J.; Kim, S. H.; Lee, S. U.; Ha, G. H.; Kang, D. G.; Ha, N. Y.; Ahn, J. S.; Cho, H. Y.; Kang, S. J.; Lee, Y. J.; Hong, S. C.; Ha, W. S.; Bae, J. M.; Lee, C. W.; Kim, J. W. Proteome analysis of human liver tumor tissue by two-dimensional gel electrophoresis and matrix assisted laser desorption/ionization-mass spectrometry for identification of disease-related proteins. Electrophoresis, 2002, 23 (24), 4142-4156.
67. Zeng, J.; Li, D. Expression and purification of His-tagged rat mitochondrial 3-ketoacyl-CoA thiolase wild-type and His352 mutant proteins. Protein Expr. Purif., 2004, 35 (2), 320-326.
68. Arakawa, H.; Takiguchi, M.; Amaya, Y.; Nagata, S.; Hayashi, H.; Mori, M. cDNA-derived amino acid sequence of rat mitochondrial 3-oxoacyl-CoA thiolase with no transient presequence: structural relationship with peroxisomal isozyme. EMBO J., 1987, 6 (5), 1361-1366.
69. Abdelmegeed, M. A.; Moon, K. H.; Hardwick, J. P.; Gonzalez, F. J.; Song, B. J. Role of peroxisome proliferator-activated receptor-alpha in fasting-mediated oxidative stress. Free Radic. Biol. Med., 2009, 47 (6), 767-778.
70. Kang, S. W.; Chang, T. S.; Lee, T. H.; Kim, E. S.; Yu, D. Y.; Rhee, S. G. Cytosolic peroxiredoxin attenuates the activation of JNK and p38 but potentiates that of ERK in Hela cells stimulated with tumor necrosis factor-alpha. J. Biol. Chem., 2004, 279 (4), 2535-2543.
71. Lee, Y. M.; Park, S. H.; Shin, D. I.; Hwang, J. Y.; Park, B., Park, Y. J.; Lee, T. H.; Chae, H. Z.; Jin, B. K.; Oh, T. H.; Oh, Y. J. Oxidative modification of peroxiredoxin is associated with drug-induced apoptotic signaling in experimental models of Parkinson disease. J. Biol. Chem., 2008, 283 (15), 9986-9998.
72. Montiel-Duarte, C.; Varela-Rey, M.; Osés-Prieto, J. A.; López-Zabalza, M. J.; Beitia, G.; Cenarruzabeitia, E.; Iraburu, M. J. 3,4-Methylenedioxymethamphetamine (Ecstasy) induces apoptosis of cultured rat liver cells. Biochim. Biophys. Acta, 2002, 1588 (1), 26-32.
73. Kim, B. J.; Ryu, S. W.; Song, B. J. JNK-and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J. Biol. Chem., 2006, 281 (30), 21256-21265.
74. Warren, M. W.; Kobeissy, F. H.; Liu, M. C.; Svetlov, S. I.; Hayes, R. L.; Gold, M. S.; Wang, K. K. Ecstasy toxicity: A comparison to methamphetamine and traumatic brain injury. J. Alzeimers Dis., 2006, 25 (4): 115-123.
75. Song, B. J.; Moon, K. H.; Olsson, N. U.; Salem, N. Jr. Prevention of alcoholic fatty liver and mitochondrial dysfunction in the rat by long-chain polyunsaturated fatty acids. J. Hepatol., 2008, 49 (2), 262-273.
76. Kuhn, D. M.; Geddes, T. J. Peroxynitrite inactivation of tryptophan hydroxylase via sulfhydryl oxidation: Coincident nitration of enzyme tyrosyl residues has minimal impact on catalytic activity. J. Biol. Chem., 1999, 274 (42), 29726-29732.
77. Kuhn, D. M.; Aretha, C. W.; Geddes, T. J. Peroxynitrite inactivation of tyrosine hydroxylase: mediation by sulfhydryl oxidation, not tyrosine nitration. J. Neurosci., 1999, 19 (23), 10289-10294.
78. Ara, J.; Przedborski, S.; Naini, A. B.; Jackson-Lewis, V.; Trifiletti, R. R.; Horwitz, J.; Ischiropoulos, H. Inactivation of tyrosine hydrozylase by niration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc. Natl. Acad. Sci. USA, 1998, 95 (13), 7659-7663.
79. Moon, K. H.; Lee, Y. M.; Song, B. J. Inhibition of hepatic mitochondrial aldehyde dehydrogenase by carbon tetrachloride through JNK-mediated phosphorylation. Free Radic. Biol. Med., 2010, 48, 391-398.
80. Wrona, M. Z.; Dryhurst, G. A putative metabolite of serotonin, trypamine-4,5-dione, is an irreversible inhibitor of tryptophan hydroxylase: Possible relevance to the serotonergic neurotoxicity of methamphetamine. Chem. Res. Toxicol., 2001, 14 (9): 1184-1192.
81. Esterbauer, H.; Schaur, R. J.; Zollner, H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med., 1991, 11 (1), 81-128.
82. Catalá, A. Lipid peroxidation of membrane phospholipids generates hydroxy-alkenals and oxidized phospholipids active in physiological and/or pathological conditions. Chem. Phys. Lipids, 2009, 157 (1), 1-11.
83. Zhou, J. F.; Chen, P.; Zhou, Y. H.; Zhang, L.; Chen, H. H. 3,4-Methylenedioxymethamphetamine (MDMA) abuse may cause oxidative stress and potential free radical damage. Free Radic. Res., 2003, 37 (5), 491-497.
84. Monks, T. J.; Lau, S. S. The pharmacology and toxicology of polyphenolic-glutathione conjugates. Annu. Rev. Pharmacol. Toxicol., 1998, 38, 229-255.
85. Stadtman, E. R.; Moskovitz, J.; Levine, R. L. Oxidation of methionine residues of proteins: biological consequences. Antioxid. Redox Signal., 2003, 5 (5), 577-582.
86. Holt, S. G.; Moore, K. P. Pathogenesis and treatment of renal dysfunction in rhabdomyolysis. Intensive Care Med., 2001, 27 (5), 803-811.
87. Topp, L.; Hando, J.; Dillon, P.; Roche, A.; Solowij, N. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend, 1999, 55 (1-2), 105-115.
88. Winstock, A. R.; Griffiths, P.; Stewart, D. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend, 2001, 64 (1), 9-17.
89. Boyd, C. J.; McCabe, S. E.; d'Arcy, H. Ecstasy use among college undergraduates: gender, race and sexual identity. J. Subst. Abuse Treat., 2003, 24 (3), 209-215.
90. Barrett, S. P.; Darredeau, C.; Pihl, R. O. Patterns of simultaneous polysubstance use in drug using university students. Hum. Psychopharmacol., 2006, 21 (4), 255-263.
91. Wu, L. T.; Parrott, A. C.; Ringwalt, C. L.; Yang, C., Blazer, D. G. The variety of ecstasy/MDMA users: results from the national epidemiologic survey on alcohol and related conditions. Am. J. Addict., 2009, 18 (6), 452-461.
92. Lieber, C. S. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol, 2004, 34 (1), 9-19.
93. Lu, Y.; Cederbaum, A. I. CYP2E1 and oxidative liver injury by alcohol. Free Radic. Biol. Med., 2008, 44 (5), 723-738.
94. Haorah, J.; Ramirez, S. H.; Floreani, N.; Gorantla, S.; Morsey, B.; Persidsky, Y. Mechanism of alcohol-induced oxidative stress and neuronal injury. Free Radic. Biol. Med., 2008, 45 (11), 1542-1550.
95. O'Keefe, J. H.; Bybee, K. A.; Lavie, C. J. Alcohol and cardiovascular health: the razor-sharp double-edged sword. J. Am. Coll. Cardiol., 2007, 50 (11), 1009-1014.
96. Izco, M.; Orio, L.; O'Shea, E.; Colado, M. I. Binge ethanol administration enhances the MDMA-induced long-term 5-HT neurotoxicity in rat brain. Psychopharmacology (Berl), 2007, 189 (4), 459-470.
97. Nutt, D. J. A tale of two Es. J. Psychopharmacol., 2006, 20 (3), 315-317.
98. Pontes, H.; Sousa, C.; Silva, R.; Fernandes, E.; Carmo, H.; Remião, F.; Carvalho, F.; Bastos, M. L. Synergistic toxicity of ethanol and MDMA towards primary cultured rat hepatocytes. Toxicology, 2008, 254 (1-2), 42-50.
99. Pontes, H.; Santos-Marques, M. J.; Fernandes, E.; Duarte, J. A.; Remião, F.; Carvalho, F.; Bastos, M. L. Effect of chronic ethanol exposure on the hepatotoxicity of ecstasy in mice: an ex vivo study. Toxicol. In Vitro, 2008, 22 (4), 910-920.
100. Pontes, H.; Duarte, J. A.; Guedes de Pinho, P.; Soares, M. E.; Fernandes, E.; Dinis-Oliveira, R. J.; Sousa, C.; Silva, R.; Carmo, H.; Casal, S.; Remião, F.; Carvalho, F.; Bastos, M. L. Chronic exposure to ethanol exacerbates MDMA-induced hyperthermia and exposes liver to severe MDMA-induced toxicity in CD1 mice. Toxicology, 2008, 252 (1-3), 64-71.
101. Upreti, V. V.; Eddington, N. D.; Moon, K. H.; Song, B. J.; Lee, I. J. Drug interaction between ethanol and 3,4-methylenedioxymethamphetamine (ecstasy). Toxicol. Lett., 2009, 188 (2), 167-172.
102. Hamida, S. B.; Tracqui, A.; de Vasconcelos, A. P.; Szwarc, E.; Lazarus, C.; Kelche, C.; Jones, B. C.; Cassel, J. C. Ethanol increases the distribution of MDMA to the rat brain: possible implications in the ethanol-induced potentiation of the psychostimulant effects of MDMA. Int. J. Neuropsychopharmacol., 2009, 12 (6), 749-759.
103. Haorah, J.; Knipe, B.; Gorantla, S.; Zheng, J.; Persidsky, Y. Alcohol-induced blood-brain barrier dysfunction is mediated via inositol 1,4,5-triphosphate receptor (IP3R)-gated intracellular calcium release. J. Neurochem., 2007, 100 (2), 324-336.
104. Sinclair, J. F.; McCaffrey, J.; Sinclair, P. R.; Bement, W. J.; Lambrecht, L. K.; Wood, S. G.; Smith, E. L.; Schenkman, J. B.; Guzelian, P. S.; Park, S. S. Ethanol increases cytochromes P450IIE, IIB1/2, and IIIA in cultured rat hepatocytes. Arch. Biochem. Biophys., 1991, 284 (2), 360-365.
105. Soh, Y.; Jeong, K. S.; Lee, I. J.; Bae, M. A.; Kim, Y. C.; Song, B. J. Selective activation of the c-Jun N-terminal protein kinase pathway during 4-hydroxynonenal-induced apoptosis of PC12 cells. Mol. Pharmacol., 2000, 58 (3), 535-541.
106. Kim, H. S.; Song, M. C.; Kwak, I. H.; Park, T. J.; Lim, I. K. Constitutive induction of p-Erk1/2 accompanied by reduced activities of protein phosphatases 1 and 2A and MKP3 due to reactive oxygen species during cellular senescence. J. Biol. Chem., 2003, 278 (39), 37497-37510.
107. Heneberg, P.; Dráber, P. Regulation of cys-based protein tyrosine phosphatases via reactive oxygen and nitrogen species in mast cells and basophils. Curr. Med. Chem., 2005, 12 (16), 1859-1871.